Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.
Adi J Klil-DroriHui YinLaurent AzoulayAlexa Del CorpoMichaël HarnoisMichel-Olivier GrattonHarold J OlneyRobert DelagePierre LaneuvilleLuigina MollicaLambert BusqueSarit E Assoulinenull nullPublished in: Cancer (2018)
Timely molecular assessment at 3 months and 12 months appears to benefit patients with CML. Adherence to timely monitoring should be encouraged, especially in low-volume treatment centers.